FatimaHafizKarzaiMD

Oncology • Bethesda, MD

Physician

Join to view full profile

Dr. Karzai is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Karzai's full profile

Already have an account?

Office
10 Center Drive
10/Room 12n226
Bethesda, MD 20892

Education & Training

George Washington University School of Medicine and Health SciencesClass of 2005

Certifications & Licensure

MD State Medical License 2009 - 2026
DC State Medical License 2005 - 2009
VA State Medical License 2005 - 2009

Clinical Trials

Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer Start of enrollment: 2019 Dec 04
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Precision-Based Genomics in Prostate Cancer Start of enrollment: 2021 Sep 14
Recruiting
Roles: Principal Investigator, Contact
Men at High Genetic Risk for Prostate Cancer Start of enrollment: 2019 Mar 27
Recruiting
Roles: Principal Investigator, Contact
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer Start of enrollment: 2019 Apr 30
Active, not recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity.
Lisa M Cordes, Fatima Karzai, Ravi A Madan
European Urology Oncology. 2024-10-01
Ferroptosis-related gene signature predicts prognosis and immune microenvironment in prostate cancer.
Hao Wang, Dalang Fang, Jinxin Zhu, Lin Liu, Liang Xue
Translational Andrology and Urology. 2024-09-30
1 citations
Quantitative Analysis of Serial Positron Emission Tomography Imaging in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide.
Shruti U Gandhy, Fatima H Karzai, Marijo Bilusic, Sheri McMahon, Lisa M Cordes
European Urology Oncology. 2024-08-01

Journal Articles

Tumor Cell Heterogeneity and Resistance; Report from the 2018 Coffey‐Holden Prostate Cancer Academy Meeting
Thomas A Hope, Kenneth J Pienta, Fatima Karzai, Simpa S Salami, Robert B Den, The Prostate

Press Mentions

Olaparib Shows Synergy with Durvalumab in mCRPCFebruary 9th, 2018
Olaparib, Durvalumab Combo Active in Prostate CancerFebruary 17th, 2017
Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t SpreadJanuary 7th, 2024